Close Menu
  • Business
  • World News
    • United States of America
    • Europe
    • Asia
    • Oceania
  • Technology
  • Sports
  • Money
  • Health
  • Life & Style
  • Shopping

Subscribe to Updates

Get the latest creative news from FooBar about art, design and business.

What's Hot

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025
Facebook X (Twitter) Instagram
Daily News
Facebook X (Twitter) Instagram
Subscribe
  • Home
  • Business

    What Size Skip Do You Need for Your Project?

    May 12, 2025

    Introduction to Share CFDs: Understanding the Basics

    December 2, 2024

    Importance of Proper Disposal in Spray Foam Removal

    August 26, 2024

    The Underlying Dynamics of Italy’s Euro: Economic Policies and Market Implications

    June 27, 2024

    The Pros and Cons of Payday Loans: Understanding the Risks and Benefits

    March 27, 2024
  • World News

    HNA Group Chairman Chen Feng Gives Speech at 2015 WTTC Global Summit: China Sees Huge Tourism Cooperation Opportunities with Europe

    October 24, 2020

    Greyrock Direct Fuel Production(TM) Recognized by the World Bank as Most Advanced Technology for Gas-to-Liquids

    September 28, 2020

    DJI to Open Flagship Store in Hong Kong

    August 29, 2020

    Micreos Secures Euros 12 Million for New Products Containing Staphefekt; Alternative to Antibiotics Can Help Millions

    June 18, 2020

    NetEase Debuts New Publicity Video in Shibuya, Triggers Speculation in Japan Game Industry

    April 19, 2020
  • Technology
  • Sports
  • Money
  • Health
  • Life & Style
  • Shopping
Daily News
Home»Health»First European Patients Enrolled in QT Vascular’s ENDURE Trial
Health

First European Patients Enrolled in QT Vascular’s ENDURE Trial

AndrewBy AndrewSeptember 15, 2014No Comments7 Mins Read0 Views
Facebook Twitter Pinterest Telegram LinkedIn Tumblr Copy Link Email
Follow Us
Google News Flipboard
Share
Facebook Twitter LinkedIn Pinterest Email Copy Link

Highlights:

  • The ENDURE Trial to assess efficacy of the novel Drug Coated Chocolate(R) PTA (Chocolate(R) Touch)
  • Chocolate(R) Touch combines Chocolate’s advantages of minimising dissections and bail-out stenting with the long-term benefits of drug coating
  • Reflects progression of Group’s new product growth strategy

Catalist-listed QT Vascular Ltd. (“QT Vascular” or together with its subsidiaries, “the Group”), a developer and manufacturer of minimally invasive medical devices for the treatment of vascular diseases, is pleased to announce that the Group has enrolled the first European patients in the ENDURE Trial in Germany. Multiple patients have already been enrolled in this study with Dr. Andrew Holden, at Auckland City Hospital, in Auckland, New Zealand.

    ENDURE is a single-arm core-lab adjudicated multi-center clinical trial conducted at top centers in Europe and New Zealand. ENDURE is designed to evaluate the efficacy of Chocolate(R) Touch at 30 days, 3 months, 6 months, and 12 months. Clinical assessment will include amputation free survival and Rutherford Grade change while core lab measurements will include late lumen loss, patency and target lesion revascularization.

    Chocolate(R) Touch is a novel drug-coated peripheral balloon that combines the acute benefits of the Chocolate(R) PTA Balloon Catheter with the potential long-term benefits of a paclitaxel-based coating. The Chocolate(R) platform represents a breakthrough in PTA balloon catheters. Used for the treatment of patients with peripheral arterial disease, it was designed to provide predictable, uniform, less traumatic dilatation and has demonstrated a very low rate of dissections and bail-out stenting(1). Paclitaxel is an anti-proliferative drug that has been shown to be efficacious in the prevention of re-narrowing of the artery over time. In addition to the benefits of the underlying Chocolate Platform, Chocolate(R) Touch is different from other Drug Coated Balloons as it does not require pre-dilatation (pre treatment with another balloon) and has a larger contact surface for drug transfer.

    In the first European patient treated at the prestigious Department of Angiology at Universitats- Herzzentrum Freiburg, Bad Krozingen, Germany, a 6.0x40mm Chocolate(R) Touch was used to successfully dilate a sub-total occlusion of the superficial femoral artery. “Chocolate’s mechanism of action minimizes vessel trauma and therefore reduces the chances of a dissection. Now coupled with a drug it could provide an option for patients to leave the hospital without a permanent implant, ” stated Professor Thomas Zeller, head, Department of Angiology.

    QT Vascular previously announced on 24 July 2014, that it has applied for CE marking approval (“CE Mark”) with respect to the Chocolate(R) Touch. The CE Mark approval, which is not expected this year, will allow for marketing of the product in the European Union. This will allow QT Vascular to capitalise on the positive demand for medical devices in Europe and the world. Chocolate(R) Touch will be the latest addition to the Group’s product pipeline. Prior to this, the Group has announced on 5 June 2014 that its wholly owned US subsidiary, TriReme Medical LLC, received notification from the United States Food and Drug Administration (FDA) of 510(K) clearance to market the Chocolate(R) Percutaneous Transluminal Coronary Angioplasty Balloon Catheter (“Chocolate PTCA”) in the United States, for the treatment of blocked arteries for coronary vascular diseases. Other products in the pipeline include the Silk PTA balloon catheter (“Silk PTA”), a version of Chocolate(R) PTA that is made for intervention in longer lesions. The Silk PTA is currently at the design feasibility stage, with CE Mark submission targeted for the first quarter of 2015.

    Dr. Eitan Konstantino, the Group’s Chief Executive Officer, commented, “We are very excited to expand the ENDURE trial in Europe and expect the enrolment to be faster with additional world class sites joining the study. It is very satisfying to see patients leaving the hospital without having to live with metal left in their leg for the rest of their life. I believe that this is where the field is trending and this is consistent with our vision. Chocolate(R) Touch represents a key milestone towards the commercialization of our second generation drug-coated balloons and will keep us competitive in the medical device market for peripheral artery diseases.”

    About Peripheral Artery Disease
    Peripheral artery disease (PAD) is caused by the build-up of fatty substances that collect and adhere to the linings of the arteries, in a process known as atherosclerosis. The build-up causes the internal lining of the artery to thicken, narrowing the artery and limiting blood flow to vital tissues and organs. Commonly affected arteries include those located in the legs, arms, neck and kidneys. The vast majority of patients with PAD also have significant concomitant coronary artery disease (CAD) and a high proportion of morbidity and mortality in these patients is related to myocardial infarction, ischemic stroke or cardiovascular death. PAD is estimated to affect 202 million people worldwide.

    About QT Vascular Ltd.
    QT Vascular Ltd. (QT Vascular) is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. The Company works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes. QT Vascular is based in Singapore with a US subsidiary, TriReme Medical LLC, in Pleasanton, California. The Company was listed on the Catalist Board of the Singapore Exchange Securities Trading Limited on 29 April 2014[2].

    References:
    (1) Das T for Mustapha J. Chocolate(R) Bar, Leipzig Interventional Course, 28-31 January, 2014.
    (2) “Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis.” 19 Oct 2013. The Lancet.

    Cautionary Note on Forward-Looking Statements

    All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as “expect”, “anticipate”, “believe”, “estimate”, “intend”, “project”, “plan”, “strategy”, “forecast” and similar expressions or future or conditional verbs such as “if”, “will”, “would”, “should”, “could”, “may” and “might”. These statements reflect the Company’s current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company undertakes any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

    The Company was listed on Catalist board of the Singapore Exchange Securities Trading Limited (the “SGX-ST”) on 29 April 2014. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”).

    This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the relevant rules of the SGX-ST. The Sponsor has not independently verified the contents of this press release.
    This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release including the correctness of any of the statements or opinions made or reports contained in this press release.

    SOURCE: QT Vascular Ltd.

    CONTACT:
    SAMUEL, kamal@financialpr.com.sg,
    or Mark LIN, marklin@financialpr.com.sg,
    Tel: (65) 6438 2990
    Fax: (65) 6438 0064,
    or Mr Mark Liew, Managing Director, Corporate Finance,
    at 20 Cecil Street,
    #21-02 Equity Plaza, Singapore 049705,
    telephone +65 6229 8088.

Follow on Google News Follow on Flipboard
Share. Facebook Twitter Pinterest LinkedIn Telegram Email Copy Link
Andrew

Related Posts

The Best Place For Heart Surgery In London

March 21, 2023

How To Shop For The Best Non Contact Thermometer?

July 23, 2021
NaN

International Science Community Welcomes China National GeneBank Opening

March 28, 2021

Comments are closed.

Featured Posts

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025

Inflatable Arches for Events: How to Make Your Brand Stand Out

March 29, 2025
Don't Miss!

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025

Inflatable Arches for Events: How to Make Your Brand Stand Out

March 29, 2025
Top Posts

Importance of Proper Disposal in Spray Foam Removal

August 26, 202418 Views

Introduction to Share CFDs: Understanding the Basics

December 2, 202411 Views

PVC Windows and Doors still the most popular choice

October 12, 201211 Views

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 202510 Views
Don't Miss

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 20253 Mins Read10 Views

Swing trading offers a practical balance between day trading and long-term investing. It gives traders…

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025

Inflatable Arches for Events: How to Make Your Brand Stand Out

March 29, 2025
Stay In Touch
  • Facebook
  • Twitter
  • Instagram
  • YouTube

Subscribe to Updates

Get the latest creative news from SmartMag about art & design.

About Us
About Us

Daily News blog provides you the latest news, guide and tips, related information and issues about the Automotive, Business, Technology, Sports, Life & Style, News Photography, and Shopping etc.

Facebook X (Twitter) Instagram
Our Picks

Why Swing Traders Need Consistently Tight Spreads for Better Position Management

June 26, 2025

What Size Skip Do You Need for Your Project?

May 12, 2025

How TradingView Helps Traders Avoid Costly Mistakes

May 2, 2025
Most Popular

Mark Ingram wins 2009 Heisman Trophy

December 15, 20090 Views

Dubai receives bailout from Abu Dhabi

December 15, 20090 Views

North Korean weapons seized in Thailand

December 15, 20090 Views
Daily News
  • Home
  • About
  • Contact
  • Privacy Policy
Copyright © 2019-2025. Daily News..

Type above and press Enter to search. Press Esc to cancel.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT